PMID- 36151002
OWN - NLM
STAT- MEDLINE
DCOM- 20221028
LR  - 20230119
IS  - 1879-3061 (Electronic)
IS  - 1043-2760 (Linking)
VI  - 33
IP  - 11
DP  - 2022 Nov
TI  - Knocking on GDF15's door for the treatment of type 2 diabetes mellitus.
PG  - 741-754
LID - S1043-2760(22)00163-1 [pii]
LID - 10.1016/j.tem.2022.08.004 [doi]
AB  - Although a large number of drugs are available for the treatment of type 2 
      diabetes mellitus (T2DM), many patients do not achieve adequate disease control 
      despite adhering to medication. Recent findings indicate that the pharmacological 
      modulation of the stress-induced cytokine growth differentiation factor 15 
      (GDF15) shows promise for the treatment of T2DM. GDF15 suppresses appetite and 
      reduces inflammation, increases thermogenesis and lipid catabolism, sustains 
      AMP-activated protein kinase (AMPK) activity, and ameliorates insulin resistance 
      and hepatic steatosis. In addition, circulating GDF15 levels are elevated in 
      response to several antidiabetic drugs, including metformin, with GDF15 mediating 
      some of their effects. Here, we review the mechanistic insights into the 
      beneficial effects of recently explored therapeutic approaches that target GDF15 
      for the treatment of T2DM.
CI  - Copyright (c) 2022 Elsevier Ltd. All rights reserved.
FAU - Aguilar-Recarte, David
AU  - Aguilar-Recarte D
AD  - Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of 
      Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain; Institute 
      of Biomedicine of the University of Barcelona (IBUB), Barcelona, Spain; Pediatric 
      Research Institute-Hospital Sant Joan de Deu, Barcelona, Spain; CIBER de Diabetes 
      y Enfermedades Metabolicas Asociadas, Instituto de Salud Carlos III, Avinguda 
      Joan XXII 27-31, E-08028 Barcelona, Spain.
FAU - Barroso, Emma
AU  - Barroso E
AD  - Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of 
      Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain; Institute 
      of Biomedicine of the University of Barcelona (IBUB), Barcelona, Spain; Pediatric 
      Research Institute-Hospital Sant Joan de Deu, Barcelona, Spain; CIBER de Diabetes 
      y Enfermedades Metabolicas Asociadas, Instituto de Salud Carlos III, Avinguda 
      Joan XXII 27-31, E-08028 Barcelona, Spain.
FAU - Palomer, Xavier
AU  - Palomer X
AD  - Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of 
      Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain; Institute 
      of Biomedicine of the University of Barcelona (IBUB), Barcelona, Spain; Pediatric 
      Research Institute-Hospital Sant Joan de Deu, Barcelona, Spain; CIBER de Diabetes 
      y Enfermedades Metabolicas Asociadas, Instituto de Salud Carlos III, Avinguda 
      Joan XXII 27-31, E-08028 Barcelona, Spain.
FAU - Wahli, Walter
AU  - Wahli W
AD  - Center for Integrative Genomics, University of Lausanne, CH-1015 Lausanne, 
      Switzerland; Lee Kong Chian School of Medicine, Nanyang Technological University 
      Singapore, Singapore 308232; ToxAlim (Research Center in Food Toxicology), INRAE, 
      UMR1331, 31300 Toulouse Cedex, France.
FAU - Vazquez-Carrera, Manuel
AU  - Vazquez-Carrera M
AD  - Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of 
      Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain; Institute 
      of Biomedicine of the University of Barcelona (IBUB), Barcelona, Spain; Pediatric 
      Research Institute-Hospital Sant Joan de Deu, Barcelona, Spain; CIBER de Diabetes 
      y Enfermedades Metabolicas Asociadas, Instituto de Salud Carlos III, Avinguda 
      Joan XXII 27-31, E-08028 Barcelona, Spain. Electronic address: 
      mvazquezcarrera@ub.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20220920
PL  - United States
TA  - Trends Endocrinol Metab
JT  - Trends in endocrinology and metabolism: TEM
JID - 9001516
RN  - 0 (Growth Differentiation Factor 15)
RN  - EC 2.7.11.31 (AMP-Activated Protein Kinases)
RN  - 0 (Hypoglycemic Agents)
RN  - 9100L32L2N (Metformin)
RN  - 0 (Lipids)
RN  - 0 (GDF15 protein, human)
SB  - IM
MH  - Humans
MH  - Growth Differentiation Factor 15/metabolism
MH  - *Diabetes Mellitus, Type 2/drug therapy/metabolism
MH  - AMP-Activated Protein Kinases/metabolism
MH  - Hypoglycemic Agents/therapeutic use
MH  - *Metformin/pharmacology/therapeutic use
MH  - Lipids
OTO - NOTNLM
OT  - AMPK
OT  - GFRAL
OT  - NAFLD
OT  - inflammation
OT  - insulin resistance
OT  - myokine
COIS- Declaration of interests No interests are declared.
EDAT- 2022/09/24 06:00
MHDA- 2022/10/29 06:00
CRDT- 2022/09/23 22:06
PHST- 2022/07/29 00:00 [received]
PHST- 2022/08/26 00:00 [revised]
PHST- 2022/08/29 00:00 [accepted]
PHST- 2022/09/24 06:00 [pubmed]
PHST- 2022/10/29 06:00 [medline]
PHST- 2022/09/23 22:06 [entrez]
AID - S1043-2760(22)00163-1 [pii]
AID - 10.1016/j.tem.2022.08.004 [doi]
PST - ppublish
SO  - Trends Endocrinol Metab. 2022 Nov;33(11):741-754. doi: 10.1016/j.tem.2022.08.004. 
      Epub 2022 Sep 20.